Products & Pipeline

KalVista is advancing a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development. We intend to develop these drug candidates as potential best-in-class treatments for hereditary angioedema (HAE) and diabetic macular edema (DME).

Our development programs have received grant funding from the JDRF, Innovate UK and the European Commission.